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 Abstract 
Preclinical evidence suggests that metformin, a widely prescribed anti-diabetic drug, may 
inhibit lung cancer progression. We investigated whether metformin use was associated with 
decreased risk of cancer-specific mortality in lung cancer patients. This study included newly 
diagnosed lung cancer patients (identified from English National Cancer Data Repository, 
1998-2009) with type 2 diabetes (based on UK Clinical Practice Research Datalink 
prescriptions and diagnosis records). Lung cancer deaths occurring up to 2012 were identified 
using Office of National Statistics mortality data and the association between metformin use 
(before and after diagnosis) and risk of lung cancer-specific mortality was calculated using Cox 
regression models. In analysis of 533 patients, we found a weak non-significant reduction in 
lung cancer-specific mortality with metformin use after diagnosis (adjusted HR, 0.86; 95% CI, 
0.68-1.09). No association was evident for metformin use before diagnosis and cancer-specific 
mortality in analysis of 1,350 patients (adjusted HR, 0.97; 95% CI, 0.86, 1.11). Associations 
were similar by duration of use. In addition, after adjustment for potential confounders, there 
was little evidence of an association between the use of other anti-diabetic medications (either 
before or after diagnosis) and lung cancer-specific mortality; including sulfonylureas, insulin 
or other anti-diabetic medications (such as thiazolidinediones). Overall, the results from this 
population-based study provide little evidence of a protective association between metformin 
use and cancer mortality in lung cancer patients. 
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 1. Introduction 
Emerging evidence from preclinical studies suggests a potential antitumour effect for 
metformin, a biguanide derivative commonly prescribed to treat type 2 diabetes, possibly due 
to the activation of AMP-activated protein kinase, leading to the inhibition of the mTOR 
signalling pathway [1]. Metformin use has been associated with improved survival in patients 
with diabetes with breast [2], colorectal [3] and prostate cancer [4]; however there are limited 
data in lung cancer patients. Constitutive mTOR signaling plays an important role in the 
development of lung cancer and in vitro and animal studies have reported antiproliferative 
effects [5] and proapoptotic effects [6], as well as the inhibition of lung tumour growth [7]. 
Few epidemiological studies have assessed the influence of metformin on lung cancer-specific 
outcomes after diagnosis. Some, but not all [8] have reported improvements in progression-
free survival [9] and disease-free survival [10,11] but these investigations were limited by small 
sample sizes [8-11], drug exposure determined at limited numbers of time-points [8-11] and a 
lack of adjustment for important baseline patient characteristics [9]. Other studies have 
investigated metformin use and overall survival [12-14], but these results could reflect 
mortality from non-cancer causes. 
In this population-based study, we investigate for the first time the impact of metformin use, 
either before or after diagnosis, on lung cancer-specific survival. Secondary analysis 
investigated the influence of other anti-diabetic medications. 
 
2. Materials and Methods 
2.1 Study design 
As described previously [15], we utilised record linkages between the English National Cancer 
Data Repository (NCDR) and the United Kingdom (UK) Clinical Practice Research Datalink 
(CPRD) to identify lung cancer patients diagnosed between 1998 and 2009. Office of National 
Statistics (ONS) mortality data provided deaths up to 2012. We restricted the cohort to those 
with a prior diagnosis of type 2 diabetes (based on a GP diagnosis of diabetes or at least one 
anti-diabetic medication prescription). Patients with type 1 diabetes were excluded and were 
defined as those with a diagnosis of type 1 diabetes in addition to at least one prescription for 
insulin before their cancer diagnosis. Patients were also excluded if they had a previous cancer 
(with the exception of non-melanoma skin cancers) or if their diagnosis date preceded CPRD 
research quality records. Ethical approval for all observational studies conducted using CPRD 
data has been obtained from a multicentre research ethics committee. 
 
2.2 Exposure data 
Data on post-diagnostic anti-diabetic medication usage was determined from general 
practitioner (GP) prescribing records contained within the CPRD according to the British 
National Formulary (BNF) [16] including metformin, sulfonylureas, insulin or other anti-
diabetic medications (including thiazolidinediones). 
 
2.3 Covariates 
The NCDR provided clinical data on tumour histology and receipt of cancer treatments 
including surgery, chemotherapy and radiotherapy. Information on lifestyle factors before 
diagnosis including smoking, alcohol and BMI was obtained from CPRD records. 
Comorbidities prior to diagnosis were derived from GP records and included those within a 
recent adaptation of the Charlson Comorbidity index [17]. A measure of deprivation was 
available from CPRD records [18]. Other medications including low-dose aspirin and statins 
were determined from GP-prescription records. Haemoglobin A1c (HbA1c) levels in the year 
prior to diagnosis were obtained from GP records. 
 
2.4 Statistical analysis 
2.4.1 Statistical analysis for anti-diabetic medication use after diagnosis 
The analysis of drug use after diagnosis used Cox regression models to produce unadjusted and 
adjusted hazard ratios (HR) and 95% confidence intervals (CI) for the association between anti-
diabetic medication usage and lung cancer-specific mortality. Patients that died in the first 6 
months after diagnosis were removed as drug use during this time is unlikely to exert an effect 
on cancer death. Drug use was treated as time-varying [19], and was lagged by 6 months to 
remove prescriptions immediately prior to death (as these may reflect end-of-life care). Dose-
response relationships were investigated for metformin use by increasing number of 
prescriptions and defined daily doses (DDDs), as defined by the WHO [20]. Sub-group 
analyses for metformin use and lung cancer mortality were carried out by pre-diagnostic drug 
use and tumour histology. Separate sensitivity analyses additionally adjusted for smoking and 
HbA1c level (among individuals with available information) and type 2 diabetes duration 
(among individuals with at least 5 years of records before diagnosis). 
 
2.4.2 Statistical analysis for anti-diabetic medication use before diagnosis 
Cox regression models were utilised to calculate unadjusted and adjusted HRs and 95% CIs for 
the association between anti-diabetic medication usage in the year prior to diagnosis and lung 
cancer-specific mortality. Patients with less than 1 year of CPRD records prior to diagnosis 
were removed. Similarly, dose-response relationships for metformin use were examined. 
Sensitivity analyses additionally adjusted for smoking, HbA1c level and type 2 diabetes 
duration. 
 
3. Results 
3.1 Patient cohort 
A total of 1,443 lung cancer patients with diabetes were identified. The analysis of anti-diabetic 
medication use after diagnosis included 533 patients, after 910 patients with less than 6 months 
follow-up were excluded. The analysis of anti-diabetic medication use before diagnosis 
included 1,350 patients, after 93 patients with less than 1 year of records prior to diagnosis 
were excluded. Patient characteristics by metformin use are listed in Table 1.  Users were more 
likely to be diagnosed more recently, be younger, be obese, to have had surgery and 
chemotherapy and to be users of statins and other anti-diabetic medications (except insulin). 
Some comorbidities were less common in users of metformin after diagnosis, Table 1. 
 
3.2 Association between anti-diabetic medication use after diagnosis and survival 
The results for the association between anti-diabetic medication use after diagnosis and 
survival are presented in Table 2. Metformin use after diagnosis was weakly associated with a 
reduction in lung cancer death, however, after adjustment for potential confounders, results 
attenuated (adjusted HR 0.86, 95% CI 0.68-1.09) and there was no significant dose-response 
relationship by increasing number of prescriptions or DDDs. In sub-group analyses, results 
were similar after stratification by pre-diagnostic metformin use (non-users: adjusted HR 0.71, 
95% CI 0.45-1.13; users: adjusted HR 0.83, 95% CI 0.41-1.69, p for interaction=0.52) and 
tumour histology (small cell lung cancer: adjusted HR 0.61, 95% CI 0.23-1.60; non-small cell 
lung cancer: adjusted HR 0.85, 95% CI 0.63-1.14), p for interaction=0.87). Additional 
adjustment for other factors did not materially alter effect estimates, including smoking 
(adjusted HR 0.86, 95% CI 0.68-1.10), HbA1c level (adjusted HR 0.88, 0.68-1.13) and diabetes 
duration (adjusted HR 0.82, 95% CI 0.62-1.10).  
 
There was no evidence of an association for sulfonylurea or insulin use. There was a suggestion 
of an increased risk of cancer mortality with the use of other anti-diabetic medication (including 
thiazolidinediones); but analysis was not significant and based on only 45 users (adjusted HR 
1.42, 95% CI 0.94-1.13). 
 
3.3 Association between anti-diabetic medication use before diagnosis and survival 
No association between metformin use prior to diagnosis and lung cancer-specific mortality 
was observed and no dose-response association was apparent, Table 2. The findings remained 
largely unchanged after additional adjustment for smoking, HbA1c level and type 2 diabetes 
duration (data not shown). Sulfonylurea, insulin and other anti-diabetic medication use were 
not associated with cancer-specific mortality, Table 2. 
3. Discussion 
Using population-based data, we  observed a 14% non-significant reduction in cancer-specific 
mortality with metformin use after diagnosis in a large cohort of lung cancer patients with pre-
existing type 2 diabetes, however this reduction was weak in magnitude and there was no clear 
evidence of a dose-response association. 
No study has investigated the influence of metformin use on cancer-specific survival in a cohort 
of lung cancer patients. Inconsistent with our findings, two previous studies reported significant 
reductions in all-cause mortality in users of metformin before [13] or after [14] lung cancer 
diagnosis. A further study reported a shorter overall survival in pre-diagnostic metformin users 
compared to non-users [12]. Unlike our investigation, previous studies did not investigate dose-
dependent relationships [12-14] and metformin use after diagnosis was time-fixed [14], thus 
potentially introducing immortal time bias. Moreover, results from studies investigating all-
cause mortality could be reflective of non-cancer mortality. 
Strengths of this study included an unselected lung cancer cohort and record linkages between 
NCDR and ONS data, allowing for robust verification of cancer diagnoses and deaths. High-
quality GP prescribing data [21] eliminated any recall bias and allowed for temporal 
associations to be examined. Furthermore, we provided an inclusive and simultaneous 
examination of all anti-diabetic medications and risk of lung cancer-specific mortality. The 
present study is the largest to investigate metformin use and outcomes after lung cancer 
diagnosis; however, a lack of statistical power in sub-group analyses is possible. Although we 
did not have information on medication compliance, it is unlikely that this is affecting our 
results because similar findings were observed in dose-response analyses. We were also unable 
to adjust for cancer stage, thus potentially introducing residual confounding.  
 
4. Conclusion 
In conclusion, the results from this novel population-based study provide little evidence that 
metformin use is associated with increased lung cancer survival. Further investigation in larger 
sample sizes is required to verify these findings.  
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Table 1. Characteristics of lung cancer patients by metformin use 
Characteristics 
Metformin use in year prior 
to  diagnosisa  
Metformin use in year after 
diagnosisb  
Metformin use after 
diagnosisb 
User n  
(%) 
Non-user n 
 (%) 
User n 
(%) 
Non-user n 
 (%) 
User n  
(%) 
Non-user n 
(%) 
 (n=1,350) (n=533) (n=533) 
Year of diagnosis: 1998-2000 45 (7) 108 (16) 25 (9) 39 (16) 23 (9) 41 (15) 
                                2001-2003 113 (17) 163 (24) 33 (12) 57 (23) 29 (12) 61 (22) 
                                2004-2006  175 (26) 191 (28) 84 (30) 58 (23) 71 (28) 71 (25) 
                                2007-2009 331 (50) 224 (33) 141 (50) 96 (38) 128 (51) 109 (39) 
 
Age at diagnosis: < 50  1 (0) 8 (1) 0 (0) 7 (3) 0 (0) 7 (2) 
                               50-59 57 (9) 57 (9) 33 (12) 12 (5) 30 (12) 15 (5) 
                               60-69 183 (28) 183 (28) 90 (32) 67 (27) 81 (32) 76 (27) 
                               70-79 286 (43) 286 (43) 116 (41) 109 (44) 104 (41) 121 (43) 
                               80-89 130 (20) 130 (20) 43 (15) 54 (22) 35 (14) 62 (22) 
                               ≥ 90 7 (1) 7 (1) 1 (0) 1 (0) 1 (0) 1 (0) 
 
Gender: Males 437 (66) 445 (65) 190 (67) 153 (61) 174 (64) 169 (65) 
 
Treatment within 6 months of cancer diagnosis 
  Surgeryc 77 (15) 47 (9) 71 (32) 26 (13) 67 (33) 30 (14) 
  Chemotherapy 153 (23) 100 (15) 100 (35) 69 (28) 90 (36) 79 (28) 
  Radiotherapy 182 (27) 196 (29) 103 (36) 100 (40) 88 (35) 115 (41) 
 
Histology: Non-small cell 371 (56) 367 (54) 206 (73) 159 (64) 184 (73) 181 (64) 
                   Small cell 86 (13) 76 (11) 38 (13) 31 (12) 33 (13) 36 (13) 
                   Missing 207 (31) 243 (35) 39 (14) 60 (24) 34 (14) 65 (23) 
 
Smoking status prior to cancer diagnosis       
  Non-smoker 101 (15.2) 99 (14) 41 (15) 35 (14) 37 (15) 39 (14) 
  Ex-smoker 331 (50) 324 (47) 143 (51) 121 (48) 127 (51) 137 (49) 
  Current smoker 220 (33) 224 (33) 92 (32) 82 (33) 80 (32) 94 (33) 
  Missing 12 (2) 39 (6) 7 (2) 12 (5) 7 (3) 12 (4) 
 
Alcohol consumption prior to diagnosis       
  Never 174 (26) 138 (20) 68 (24) 54 (22) 61 (24) 61 (22) 
  Ever 449 (68) 466 (68) 198 (70) 171 (68) 175 (70) 194 (69) 
  Missing 41 (6) 82 (12) 17 (6) 25 (10) 15 (6) 27 (10) 
 
BMI (kg/m2) prior to diagnosis: mean (sd)       
  Underweight (<18.5) 11 (2) 20 (3) 4 (1) 8 (3) 4 (2) 8 (3) 
  Normal (18.5 to 25)  174 (26) 211 (31) 58 (21) 68 (27) 52 (21) 74 (26) 
  Overweight (25-30) 236 (36) 239 (35) 103 (36) 95 (38) 88 (35) 110 (39) 
  Obese (>30) 219 (33) 156 (23) 106 (38) 67 (27) 96 (38) 77 (27) 
  Missing 24 (4) 60 (9) 12 (4) 12 (5) 11 (4) 13 (5) 
 
Deprivation fifth: 1st (least deprived) 102 (15) 102 (15) 52 (18) 36 (14) 45 (18) 43 (15) 
                                2nd 132 (20) 141 (21) 53 (19) 60 (24) 49 (20) 64 (23) 
                                3rd  120 (18) 143 (21) 50 (18) 52 (21) 44 (18) 58 (21) 
                                4th  150 (23) 154 (23) 57 (20) 50 (20) 49 (20) 58 (21) 
                                5th (most deprived) 158 (24) 144 (21) 68 (24) 51 (20) 61 (24) 58 (21) 
                                Missing 2 (0) 2 (0) 3 (1) 1 (0) 3 (1) 1 (0) 
 
Comorbidity prior to cancer diagnosis       
  Cerebrovascular disease 79 (12) 97 (14) 22 (8) 37 (15) 19 (8) 40 (14) 
  Chronic pulmonary disease 174 (26) 199 (29) 68 (24) 81 (32) 64 (26) 85 (30) 
  Congestive heart disease 60 (9) 80 (12) 16 (6) 26 (10) 13 (5) 29 (10) 
  Myocardial infarction 103 (16) 106 (16) 36 (13) 38 (15) 34 (14) 40 (14) 
  Peptic ulcer disease 49 (7) 53 (8) 24 (9) 19 (8) 18 (7) 25 (9) 
  Peripheral vascular disease 129 (19) 115 (17) 43 (15) 35 (14) 39 (16) 39 (14) 
  Renal disease 91 (14) 118 (17) 30 (11) 49 (20) 27 (11) 52 (18) 
 
Other medication use after diagnosis       
  Low-dose aspirin used  371 (56) 350 (51) 157 (56) 123 (49) 136 (54) 106 (38) 
  Statin used  461 (69) 328 (48) 201 (71) 130 (52) 184 (73) 117 (42) 
 
Anti-diabetic medication after diagnosis       
  Sulfonylureasd 328 (49) 236 (34) 114 (40) 92 (37) 126 (50) 84 (30) 
  Insulind 80 (12) 102 (15) 27 (10) 46 (18) 41 (16) 51 (18) 
  Other ADDsd 94 (14) 30 (4) 37 (13) 13 (5) 30 (12) 15 (5) 
 
HbA1c level in year prior to diagnosis       
  ≤6.5% 161 (24) 223 (34) 62 (22) 87 (35) 54 (22) 95 (34) 
  >6.5% 478 (72) 340 (50) 206 (73) 127 (51) 184 (73) 149 (53) 
  Missing 25 (4) 113 (17) 15 (5) 36 (14) 13 (5) 38 (14) 
a Analysis includes lung cancer patients who have more than 1 year of records prior to diagnosis. b Analysis includes lung 
cancer patients who live more than 6 months after diagnosis. c Excluding cancer patients from Thames Registry as surgery 
information not available. d Other medication use after diagnosis for metformin use after diagnosis columns, other 
medication use in year prior to diagnosis for metformin use in year prior to diagnosis columns. ADD= anti-diabetic drug

a Analysis includes lung cancer patients who live more than 6 months after diagnosis 
b Adjusted analyses controlled for year of diagnosis, age at diagnosis, sex, radiotherapy within 6 months, chemotherapy within 6 months, comorbidities (prior to diagnosis, including cerebrovascular 
disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other anti-diabetic  medication use 
(after diagnosis, as time varying covariates, including metformin, sulfonylureas, insulin and other ADDs), other medication use (after diagnosis, as time varying covariates, specifically low-dose 
aspirin and statins) and deprivation (in fifths). 
c Medication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage and a user after this time, excludes deaths in the first 
6 months after cancer diagnosis. 
d Medication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage, a user of 0 to 12 prescriptions from 6 months after 
first prescription to 6 months after 12th prescription (or 365 DDDs) and a greater user after this time, excludes deaths in the 6 months after cancer diagnosis. 
e Analysis includes lung cancer patients who have more than 1 year of records prior to diagnosis 
Table 2: Association between anti-diabetic medication usage and cancer-specific mortality in lung cancer patients with type 2 diabetes 
 Users   Non-users   
 
 
Cancer-
specific 
deaths 
All 
patients 
Person 
years 
 
Cancer-
specific 
deaths 
All 
patients 
Person 
years 
Unadjusted  
HR (95% CI) 
 
P 
 
Adjusted  
HR (95% CI) 
 
 
P 
ADD use after diagnosisa,b       (n=533)  (n=533)  
 
  Metformin usec 149 251 386 211 282 305 0.80 (0.66-1.00) 0.05 0.86 (0.68-1.09) 0.21 
 
 Metformin use 1-11 prescriptionsd 119 159 217 211 282 305 0.82 (0.65-1.03) 0.09 0.87 (0.68-1.11) 0.26 
 Metformin use ≥12 prescriptionsd 30 92 169    0.75 (0.47-1.17) 0.20 0.82 (0.51-1.30) 0.40 
 
 Metformin use 1-365 DDDsd 121 172 236 211 282 305 0.79 (0.63-0.99) 0.05 0.84 (0.65-1.07) 0.16 
 Metformin use ≥365 DDDsd 28 79 150    0.91 (0.56-1.48) 0.71 1.01 (0.62-1.67) 0.96 
 
  Sulfonylurea usec 132 210 278 228 323 412 1.10 (0.88-1.37) 0.42 1.10 (0.87-1.40) 0.41 
 
  Insulin usec 55 92 137 305 441 554 1.02 (0.75-1.34) 0.96 1.06 (0.78-1.45) 0.70 
 
  Other ADD usec 30 45 54 330 488 637 1.21 (0.83-1.76) 0.32 1.42 (0.94-1.13) 0.09 
 
  ADD use in year prior to diagnosise,f      (n=1,350)  (n=1,350)  
 
  Metformin use 514 664 536 558 686 505 0.89 (0.79-1.00) 0.06 0.97 (0.86-1.11) 0.67 
 
 Metformin use 1-11 prescriptions 375 483 403 558 686 505 0.88 (0.77-1.00) 0.05 0.95 (0.83-1.10) 0.51 
 Metformin use ≥12 prescriptions 139 181 133    0.92 (0.76-1.11) 0.38 1.03 (0.85-1.25) 0.77 
 
 Metformin use 1-365 DDDs 455 577 467 558 686 505 0.91 (0.80-1.02) 0.12 0.98 (0.86-1.12) 0.78 
 Metformin use ≥365 DDDs 59 87 69    0.78 (0.60-1.02) 0.07 0.90 (0.68-1.19) 0.47 
 
  Sulfonylurea use 453 564 389 619 786 651 1.11 (0.99-1.26) 0.08 1.07 (0.94-1.21) 0.31 
 
  Insulin use 143 182 148 929 1,168 892 0.93 (0.78-1.11) 0.40 1.00 (0.84-1.21) 0.97 
 
  Other ADD use 99 124 103 973 1,226 938 0.91 (0.74-1.13) 0.40 0.98 (0.79-1.21) 0.84 
f Adjusted analyses controlled for year of diagnosis, age at diagnosis, sex, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, 
diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other anti-diabetic  medication use (in year prior to diagnosis, including metformin, sulfonylureas, 
insulin and other ADDs), other medication use (in year prior to diagnosis, specifically low-dose aspirin and statins) and deprivation (in fifths). 
ADD= anti-diabetic drug 
 
 
